三諾生物(300298.SZ)擬發行5億元可轉債 初始轉股價35.35元/股
格隆匯12月16日丨三諾生物(300298.SZ)公佈,公司擬發行5億元可轉債,可轉債簡稱為“三諾轉債”,債券代碼為“123090”,初始轉股價格為35.35元/股。
本次可轉債發行原股東優先配售日與網上申購日同為2020年12月21日(T日),網上申購時間為T日9:15-11:30,13:00-15:00。
本次發行的募集資金總額不超過5億元(含),扣除發行費用後擬用於iPOCT(智慧化即時檢測)產品產能擴建項目、CGMS(連續血糖監測系統)產能建設項目及部分補流項目。除補充流動資金項目外,公司的其他募集資金投資項目投入均為資本性支出,建設週期為三年。
網上路演時間:2020年12月18日(星期五)15:00-17:00
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.